Patent expiration for blockbuster drugs, global competition, healthcare reform, mega-mergers and increased regulatory challenges are all in the midst of a global economic crisis. This is truly an extraordinary time for the pharmaceutical industry; a time where pressures to reduce the cost of their products are crucial to company survival. Raw materials, consumables, labor, energy and initial capital investment comprise the majority of the manufacturing cost of goods for biologic and pharmaceutical drug products. The cost of raw materials, consumables and energy are cost components that have been addressed by negotiation with suppliers, high volume purchasing or more efficient use of these supplies. The initial capital investment of facilities is a component that has been escalating over the past two decades with increases in facility scale, greater complexity and regulatory concerns.